Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H45NO5S |
Molecular Weight | 507.726 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O
InChI
InChIKey=KPVIXBKIJXZQJX-CSOZIWFHSA-N
InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16?,17-,18+,20+,21+,22+,24-,25-,26+,27-,28-/m0/s1
Molecular Formula | C28H45NO5S |
Molecular Weight | 507.726 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
LEFAMULIN is a pleuromutilin antibiotic under development for the treatment of community-acquired bacterial pneumonia, as well as acute bacterial skin and skin structure infections. It inhibits bacterial protein synthesis by binding to the peptidyl transferase center of the 50S ribosome, resulting in the cessation of bacterial growth.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.6 μg/mL |
150 mg 2 times / day steady-state, intravenous dose: 150 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.24 μg/mL |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
3.5 μg/mL |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.24 μg/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28.6 μg × h/mL |
150 mg 2 times / day steady-state, intravenous dose: 150 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
32.7 μg × h/mL |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
27 μg × h/mL |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
30.7 μg × h/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8 h |
150 mg 2 times / day steady-state, intravenous dose: 150 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8 h |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
8 h |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8 h |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEFAMULIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 2 times / day multiple, intravenous Highest studied dose Dose: 200 mg, 2 times / day Route: intravenous Route: multiple Dose: 200 mg, 2 times / day Sources: |
healthy, adults Health Status: healthy Age Group: adults Sources: |
|
400 mg single, intravenous Highest studied dose Dose: 400 mg Route: intravenous Route: single Dose: 400 mg Sources: |
healthy, adults Health Status: healthy Age Group: adults Sources: |
|
600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
healthy, adults Health Status: healthy Age Group: adults Sources: |
|
750 mg single, oral Highest studied dose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: |
healthy, adults Health Status: healthy Age Group: adults Sources: |
|
600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Other AEs: Diarrhea, Nausea... Other AEs: Diarrhea (12%) Sources: Nausea (5%) Vomiting (3%) Alanine aminotransferase increased (2%) Aspartate aminotransferase increased (2%) Liver function test increased (2%) Anemia (<2%) Thrombocytopenia (<2%) Atrial fibrillation (<2%) Palpitations (<2%) Abdominal pain (<2%) Constipation (<2%) Dyspepsia (<2%) Epigastric discomfort (<2%) Gastritis erosive (<2%) Clostridium difficile colitis (<2%) Oropharyngeal candidiasis (<2%) Vulvovaginal candidiasis (<2%) Somnolence (<2%) Urinary retention (<2%) Anxiety (<2%) Diarrhea (12%) Nausea (5%) Vomiting (3%) Alanine aminotransferase increased (2%) Aspartate aminotransferase increased (2%) Liver function test increased (2%) Anemia (<2%) Thrombocytopenia (<2%) Atrial fibrillation (<2%) Palpitations (<2%) Abdominal pain (<2%) Constipation (<2%) Dyspepsia (<2%) Epigastric discomfort (<2%) Gastritis erosive (<2%) Clostridium difficile colitis (<2%) Oropharyngeal candidiasis (<2%) Vulvovaginal candidiasis (<2%) Somnolence (<2%) Urinary retention (<2%) Anxiety (<2%) |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Other AEs: Infusion site pain, Infusion site phlebitis... Other AEs: Infusion site pain (7%) Sources: Infusion site phlebitis (7%) Injection site reaction (7%) Alanine aminotransferase increased (3%) Aspartate aminotransferase increased (3%) Liver function test increased (3%) Nausea (3%) Hypokalemia (3%) Insomnia (3%) Headache (2%) Anemia (<2%) Thrombocytopenia (<2%) Atrial fibrillation (<2%) Palpitations (<2%) Abdominal pain (<2%) Constipation (<2%) Dyspepsia (<2%) Epigastric discomfort (<2%) Gastritis erosive (<2%) Clostridium difficile colitis (<2%) Oropharyngeal candidiasis (<2%) Vulvovaginal candidiasis (<2%) Somnolence (<2%) Urinary retention (<2%) Anxiety (<2%) Infusion site pain (7%) Infusion site phlebitis (7%) Injection site reaction (7%) Alanine aminotransferase increased (3%) Aspartate aminotransferase increased (3%) Liver function test increased (3%) Nausea (3%) Hypokalemia (3%) Insomnia (3%) Headache (2%) Anemia (<2%) Thrombocytopenia (<2%) Atrial fibrillation (<2%) Palpitations (<2%) Abdominal pain (<2%) Constipation (<2%) Dyspepsia (<2%) Epigastric discomfort (<2%) Gastritis erosive (<2%) Clostridium difficile colitis (<2%) Oropharyngeal candidiasis (<2%) Vulvovaginal candidiasis (<2%) Somnolence (<2%) Urinary retention (<2%) Anxiety (<2%) |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Disc. AE: Infectious pleural effusion, Lung abscess... Other AEs: Infectious pleural effusion, Lung abscess... AEs leading to discontinuation/dose reduction: Infectious pleural effusion (1 patient) Other AEs:Lung abscess (1 patient) Pneumonia (1 patient) Pulmonary tuberculosis (1 patient) Acute respiratory distress syndrome (1 patient) Acute respiratory failure (1 patient) Chronic obstructive pulmonary disease (1 patient) Pulmonary edema (1 patient) Vomiting (2 patients) Abdominal pain upper (1 patient) Infusion site phlebitis (1 patient) Injection site reaction (1 patient) Hepatitis toxic (1 patient) Infectious pleural effusion (1 patient) Sources: Lung abscess (1 patient) Pneumonia (1 patient) Pulmonary tuberculosis (1 patient) Acute respiratory distress syndrome (1 patient) Acute respiratory failure (1 patient) Chronic obstructive pulmonary disease (1 patient) Pulmonary edema (1 patient) Vomiting (2 patients) Abdominal pain upper (1 patient) Infusion site phlebitis (1 patient) Injection site reaction (1 patient) Hepatitis toxic (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | 12% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Diarrhea | 12% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Alanine aminotransferase increased | 2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Alanine aminotransferase increased | 2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Aspartate aminotransferase increased | 2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Aspartate aminotransferase increased | 2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Liver function test increased | 2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Liver function test increased | 2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Vomiting | 3% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Vomiting | 3% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Nausea | 5% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Nausea | 5% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Abdominal pain | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Abdominal pain | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Anemia | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Anemia | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Anxiety | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Anxiety | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Atrial fibrillation | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Atrial fibrillation | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Clostridium difficile colitis | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Clostridium difficile colitis | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Constipation | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Constipation | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Dyspepsia | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Dyspepsia | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Epigastric discomfort | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Epigastric discomfort | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Gastritis erosive | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Gastritis erosive | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Oropharyngeal candidiasis | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Oropharyngeal candidiasis | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Palpitations | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Palpitations | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Somnolence | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Somnolence | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Thrombocytopenia | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Thrombocytopenia | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Urinary retention | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Urinary retention | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Vulvovaginal candidiasis | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Vulvovaginal candidiasis | <2% | 600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Headache | 2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Headache | 2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Alanine aminotransferase increased | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Alanine aminotransferase increased | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Aspartate aminotransferase increased | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Aspartate aminotransferase increased | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Hypokalemia | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Hypokalemia | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Insomnia | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Insomnia | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Liver function test increased | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Liver function test increased | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Nausea | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Nausea | 3% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Infusion site pain | 7% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Infusion site pain | 7% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Infusion site phlebitis | 7% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Infusion site phlebitis | 7% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Injection site reaction | 7% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Injection site reaction | 7% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Abdominal pain | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Abdominal pain | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Anemia | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Anemia | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Anxiety | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Anxiety | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Atrial fibrillation | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Atrial fibrillation | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Clostridium difficile colitis | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Clostridium difficile colitis | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Constipation | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Constipation | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Dyspepsia | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Dyspepsia | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Epigastric discomfort | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Epigastric discomfort | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Gastritis erosive | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Gastritis erosive | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Oropharyngeal candidiasis | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Oropharyngeal candidiasis | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Palpitations | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Palpitations | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Somnolence | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Somnolence | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Thrombocytopenia | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Thrombocytopenia | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Urinary retention | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Urinary retention | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Vulvovaginal candidiasis | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Vulvovaginal candidiasis | <2% | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Abdominal pain upper | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Acute respiratory distress syndrome | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Acute respiratory failure | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Chronic obstructive pulmonary disease | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Hepatitis toxic | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Infectious pleural effusion | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Infusion site phlebitis | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Injection site reaction | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Lung abscess | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Pneumonia | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Pulmonary edema | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Pulmonary tuberculosis | 1 patient | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Abdominal pain upper | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Acute respiratory distress syndrome | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Acute respiratory failure | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Chronic obstructive pulmonary disease | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Hepatitis toxic | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Infectious pleural effusion | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Infusion site phlebitis | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Injection site reaction | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Lung abscess | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Pneumonia | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Pulmonary edema | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Pulmonary tuberculosis | 1 patient Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Vomiting | 2 patients | 150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Vomiting | 2 patients Disc. AE |
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral Recommended Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Route: intravenous|oral Route: multiple|multiple Dose: 150 | 600 mg|mg, 2 | 2 times / day|day Sources: |
unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 24.5 uM] | ||||
no [IC50 41 uM] | ||||
no [IC50 >122 uM] | ||||
no [IC50 >122 uM] | ||||
no [IC50 >122 uM] | ||||
no [IC50 >200 uM] | ||||
no [IC50 >200 uM] | ||||
no [IC50 >200 uM] | ||||
no [IC50 >200 uM] | ||||
no [IC50 >200 uM] | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
weak [IC50 122 uM] | ||||
weak [IC50 122 uM] | ||||
Page: 50;126;270 |
weak [IC50 13.76 uM] | |||
yes [IC50 0.297 uM] | ||||
yes [IC50 42.2 uM] | ||||
yes [IC50 76.4 uM] | ||||
yes [Ki 0.86 uM] | ||||
Page: 126;228;270 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
Page: 125;269;270 |
yes | |||
Page: 126;269;270 |
yes | yes (co-administration study) Comment: increased the arithmetic mean Cmax and AUC0-inf of LEF by 58% and 165%, respectively, when administered with ketoconazole (strong inhibitor); reduced the arithmetic mean Cmax and AUC0-inf of LEF by 57% and 72%, respectively, when administered with rifampin (strong inducer) Page: 126;269;270 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. | 2016 Apr |
|
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States. | 2016 Jul |
|
Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. | 2018 Sep |
|
Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. | 2019 Jan |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27161634
Lefamulin was evaluated against various Streptococcus pneumoniae serotypes that were collected from adults with lower respiratory tract infections. Lefamulin exhibited MIC50 and MIC90 values of 0.12 and 0.25 μg/ml, respectively, against the entire collection (n = 822). Similar results were obtained for lefamulin against each of the most common serotypes as well as against multidrug-resistant isolates and strains that are nonsusceptible to ceftriaxone or erythromycin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:50:35 GMT 2025
by
admin
on
Mon Mar 31 22:50:35 GMT 2025
|
Record UNII |
21904A5386
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2198944
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
m12169
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL3291398
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
9849
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
21904A5386
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
Lefamulin
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
5348
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
100000176088
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
Lefamulin
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
21904A5386
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
C166531
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
DB12825
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
1061337-51-6
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
CD-31
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
58076382
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY | |||
|
DTXSID101027896
Created by
admin on Mon Mar 31 22:50:35 GMT 2025 , Edited by admin on Mon Mar 31 22:50:35 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR | |||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
EXCRETED UNCHANGED |
Following IV administration
AMOUNT EXCRETED
URINE
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
Following IV administration
AMOUNT EXCRETED
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||